Description
MART-1 is an endogenous melanoma-associated antigen that can be used in the development of vaccines to induce an immune response against cancerous cells expressing melanoma antigens. Vaccines using MART-1 conjugates have shown some anticancer chemotherapeutic efficacy in clinical trials.